• Costs: We estimated costs from Quentin (2012) . Based on the total economic cost of $26.41 per girl for approximately 50,000 girls, we assumed that each girl contributed $10 to overhead costs, for a total of $500,000. We multiplied this total by 1.5 to reflect the larger population in our sample, for a total of $750,000 in fixed costs. We assumed an incremental economic cost (i.e. variable cost per patient) of approximately $15/fully vaccinated girl ($10 in non-vaccine costs and a $5 vaccine cost). We assumed that 100,000 girls were vaccinated per year.
• Benefits: We used Tanzanian incidence of cervical cancer by age, reported in Campos (2016) (Supporting Information, Table D) . We assumed that benefits were proportional to the number of vaccinated women in an age group, multipled by the cervical cancer incidence in that age group. We scaled benefits to obtain an ICER in a reasonable range (e.g. Kim (2013 ( ), Fesenfeld (2013 ).
